Your browser doesn't support javascript.
loading
Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death.
Na, Rong; Zheng, S Lilly; Han, Misop; Yu, Hongjie; Jiang, Deke; Shah, Sameep; Ewing, Charles M; Zhang, Liti; Novakovic, Kristian; Petkewicz, Jacqueline; Gulukota, Kamalakar; Helseth, Donald L; Quinn, Margo; Humphries, Elizabeth; Wiley, Kathleen E; Isaacs, Sarah D; Wu, Yishuo; Liu, Xu; Zhang, Ning; Wang, Chi-Hsiung; Khandekar, Janardan; Hulick, Peter J; Shevrin, Daniel H; Cooney, Kathleen A; Shen, Zhoujun; Partin, Alan W; Carter, H Ballentine; Carducci, Michael A; Eisenberger, Mario A; Denmeade, Sam R; McGuire, Michael; Walsh, Patrick C; Helfand, Brian T; Brendler, Charles B; Ding, Qiang; Xu, Jianfeng; Isaacs, William B.
Afiliação
  • Na R; Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China; Program for Isaacs Personalized Cancer Care, IL, USA.
  • Zheng SL; Program for Isaacs Personalized Cancer Care, IL, USA; Department of Surgery, NorthShore University HealthSystem, Evanston, IL, USA.
  • Han M; Department of Urology and the James Buchanan Brady Urologic Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Yu H; Program for Isaacs Personalized Cancer Care, IL, USA; State Key Laboratory of Genetic Engineering, School of Life Science, Fudan University, Shanghai, China.
  • Jiang D; Program for Isaacs Personalized Cancer Care, IL, USA; State Key Laboratory of Genetic Engineering, School of Life Science, Fudan University, Shanghai, China.
  • Shah S; Program for Isaacs Personalized Cancer Care, IL, USA.
  • Ewing CM; Department of Urology and the James Buchanan Brady Urologic Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Zhang L; Department of Urology and the James Buchanan Brady Urologic Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Novakovic K; Program for Isaacs Personalized Cancer Care, IL, USA; Department of Surgery, NorthShore University HealthSystem, Evanston, IL, USA.
  • Petkewicz J; Program for Isaacs Personalized Cancer Care, IL, USA; Department of Surgery, NorthShore University HealthSystem, Evanston, IL, USA.
  • Gulukota K; Department of Center for Molecular Medicine, NorthShore University HealthSystem, Evanston, Illinois, USA.
  • Helseth DL; Department of Center for Molecular Medicine, NorthShore University HealthSystem, Evanston, Illinois, USA.
  • Quinn M; Program for Isaacs Personalized Cancer Care, IL, USA; Department of Surgery, NorthShore University HealthSystem, Evanston, IL, USA.
  • Humphries E; Department of Urology and the James Buchanan Brady Urologic Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Wiley KE; Department of Urology and the James Buchanan Brady Urologic Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Isaacs SD; Department of Urology and the James Buchanan Brady Urologic Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Wu Y; Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China.
  • Liu X; Program for Isaacs Personalized Cancer Care, IL, USA; State Key Laboratory of Genetic Engineering, School of Life Science, Fudan University, Shanghai, China.
  • Zhang N; Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China; Program for Isaacs Personalized Cancer Care, IL, USA.
  • Wang CH; Program for Isaacs Personalized Cancer Care, IL, USA.
  • Khandekar J; Department of Center for Molecular Medicine, NorthShore University HealthSystem, Evanston, Illinois, USA.
  • Hulick PJ; Department of Medicine, NorthShore University HealthSystem, Evanston, IL, USA.
  • Shevrin DH; Department of Medicine, NorthShore University HealthSystem, Evanston, IL, USA.
  • Cooney KA; Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA.
  • Shen Z; Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China.
  • Partin AW; Department of Urology and the James Buchanan Brady Urologic Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Carter HB; Department of Urology and the James Buchanan Brady Urologic Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Carducci MA; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
  • Eisenberger MA; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
  • Denmeade SR; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
  • McGuire M; Department of Surgery, NorthShore University HealthSystem, Evanston, IL, USA.
  • Walsh PC; Department of Urology and the James Buchanan Brady Urologic Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Helfand BT; Program for Isaacs Personalized Cancer Care, IL, USA; Department of Surgery, NorthShore University HealthSystem, Evanston, IL, USA.
  • Brendler CB; Program for Isaacs Personalized Cancer Care, IL, USA; Department of Surgery, NorthShore University HealthSystem, Evanston, IL, USA.
  • Ding Q; Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China. Electronic address: qiangd.urol@gmail.com.
  • Xu J; Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China; Program for Isaacs Personalized Cancer Care, IL, USA; Department of Surgery, NorthShore University HealthSystem, Evanston, IL, USA; State Key Laboratory of Genetic Engineering, School of Life Science, Fudan University,
  • Isaacs WB; Department of Urology and the James Buchanan Brady Urologic Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, MD, USA. Electronic address: wisaacs@jhmi.edu.
Eur Urol ; 71(5): 740-747, 2017 05.
Article em En | MEDLINE | ID: mdl-27989354
ABSTRACT

BACKGROUND:

Germline mutations in BRCA1/2 and ATM have been associated with prostate cancer (PCa) risk.

OBJECTIVE:

To directly assess whether germline mutations in these three genes distinguish lethal from indolent PCa and whether they confer any effect on age at death. DESIGN, SETTING, AND

PARTICIPANTS:

A retrospective case-case study of 313 patients who died of PCa and 486 patients with low-risk localized PCa of European, African, and Chinese descent. Germline DNA of each of the 799 patients was sequenced for these three genes. OUTCOME MEASUREMENTS AND STATISTICAL

ANALYSIS:

Mutation carrier rates and their effect on lethal PCa were analyzed using the Fisher's exact test and Cox regression analysis, respectively. RESULTS AND

LIMITATIONS:

The combined BRCA1/2 and ATM mutation carrier rate was significantly higher in lethal PCa patients (6.07%) than localized PCa patients (1.44%), p=0.0007. The rate also differed significantly among lethal PCa patients as a function of age at death (10.00%, 9.08%, 8.33%, 4.94%, and 2.97% in patients who died ≤ 60 yr, 61-65 yr, 66-70 yr, 71-75 yr, and over 75 yr, respectively, p=0.046) and time to death after diagnosis (12.26%, 4.76%, and 0.98% in patients who died ≤ 5 yr, 6-10 yr, and>10 yr after a PCa diagnosis, respectively, p=0.0006). Survival analysis in the entire cohort revealed mutation carriers remained an independent predictor of lethal PCa after adjusting for race and age, prostate-specific antigen, and Gleason score at the time of diagnosis (hazard ratio=2.13, 95% confidence interval 1.24-3.66, p=0.004). A limitation of this study is that other DNA repair genes were not analyzed.

CONCLUSIONS:

Mutation status of BRCA1/2 and ATM distinguishes risk for lethal and indolent PCa and is associated with earlier age at death and shorter survival time. PATIENT

SUMMARY:

Prostate cancer patients with inherited mutations in BRCA1/2 and ATM are more likely to die of prostate cancer and do so at an earlier age.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Mutação em Linhagem Germinativa / Proteína BRCA1 / Proteína BRCA2 / Proteínas Mutadas de Ataxia Telangiectasia Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Mutação em Linhagem Germinativa / Proteína BRCA1 / Proteína BRCA2 / Proteínas Mutadas de Ataxia Telangiectasia Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article